Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]

Maria Carmen De Santis, Christine Campbell, Faye Samy, Fiorenza De Rose, Bruno Meduri, Matteo Lambertini, Christos Sotiriou, Maria Grazia Carnevale, Antonella Ferro, Cristina Saura, Anup Choudhury, Carlotta Giandini, Paolo Verderio, Saranya Chumsri, Valentina Appierto, Martine Piccart, Giancarlo Pruneri, Riccardo Ray Colciago, Evandro de Azambuja, Serena Di Cosimo · 2026

Read Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)] by Maria Carmen De Santis, Christine Campbell, Faye Samy, Fiorenza De Rose, Bruno Meduri, Matteo Lambertini, Christos Sotiriou, Maria Grazia Carnevale, Antonella Ferro, Cristina Saura, Anup Choudhury, Carlotta Giandini, Paolo Verderio, Saranya Chumsri, Valentina Appierto, Martine Piccart, Giancarlo Pruneri, Riccardo Ray Colciago, Evandro de Azambuja, Serena Di Cosimo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427515.txt.

Description

Maria Carmen De Santis and colleagues re-examined radiation after mastectomy in HER2-positive breast cancer using the ALTTO trial in a 2026 retrospective exploratory analysis. Postmastectomy radiation improves local control and survival in early breast cancer generally, yet its value alongside modern anti-HER2 therapy was unclear. The analysis included every ALTTO participant who had a mastectomy, regardless of randomization arm, within the phase III lapatinib and trastuzumab optimization trial.

Prospectively collected trial data give cleaner follow-up than typical chart reviews for judging radiation benefit in this subgroup. Results can refine which HER2-positive patients still need chest wall radiation after mastectomy. The trial ran at scale across lands, so its stored data hold a breadth no lone site could match when a sub group this size is in view.

Catalog record

CREATORMaria Carmen De Santis, Christine Campbell, Faye Samy, Fiorenza De Rose, Bruno Meduri, Matteo Lambertini, Christos Sotiriou, Maria Grazia Carnevale, Antonella Ferro, Cristina Saura, Anup Choudhury, Carlotta Giandini, Paolo Verderio, Saranya Chumsri, Valentina Appierto, Martine Piccart, Giancarlo Pruneri, Riccardo Ray Colciago, Evandro de Azambuja, Serena Di Cosimo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40481
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13427515

Browse the full library · About the Tower of Babel